OVERVIEW
The policy documents requirements necessary for coverage of omalizumab therapy services for individuals with allergic asthma.

PRIOR AUTHORIZATION
Preauthorization is required for BlueCHiP for Medicare and recommended for Commercial products.

POLICY STATEMENT
BlueCHiP for Medicare and Commercial products:

Omalizumab therapy is medically necessary when all of the criteria are met.

For contracts with specialty drug coverage, please refer to the member agreement for benefits and prior authorization guidelines.

MEDICAL CRITERIA
Criteria 1 and 2 must be met for the initial therapy.
Criteria 1 and 3 must be met for the continuation of use.

1. Omalizumab may be considered medically necessary in adults and adolescents (12 years of age and older) with allergy-induced asthma when all of the following criteria is met:
   a. Moderate to severe persistent asthma; and
   b. A positive skin test or in-vitro reactivity to a perennial aeroallergen; and
   c. Symptoms that are inadequately controlled with inhaled corticosteroids at the optimal dose and/or combination agents or cannot tolerate these medications; and
   d. A pretreatment serum IgE level is equal to or greater than 30 IU/mL; and
   e. An FEV1 < 80% predicted; and
   f. Symptoms are inadequately controlled despite optimal use of a long acting beta-2 agonist or leukotriene modifier/theophylline; and
   g. Adherence/persistent with prescribed asthma treatments; and
   h. A nonsmoker.

2. For the initial use of Omalizumab therapy all of the following criteria must be met:
   a. A diagnosis of moderate or severe persistent asthma; and
   b. And are 12 years of age or older; and
   c. Omalizumab will be used in combination with other medications for long-term control of asthma; and
   d. Will have a short-acting beta-agonist available for rescue therapy; and
   e. Omalizumab will be given in a controlled health care setting with access to emergency medications if needed; and
   f. Will be provided with an epinephrine self-injection pen in case of delayed allergic or anaphylactic reaction; and
   g. Meet criteria for initial therapy or continuation of therapy as listed in this policy.
3. For the continuation of use of Omalizumab therapy all of the following criteria must be met:
   a. Asthma control has improved on Omalizumab treatment; or
   b. Documented clinical reason for lack of improvement.

**BACKGROUND**

Omalizumab (Xolair) is a recombinant DNA-derived humanized monoclonal anti-immunoglobulin E (IgE) antibody that selectively binds to human IgE. Omalizumab has been shown to decrease the incidence of asthma exacerbation in patients with allergy-induced asthma.

Allergy tests are required to identify patients who may be candidates for omalizumab therapy. Initial administration or prescription should be given by a consulting specialist with significant training and experience in the diagnosis and treatment of asthma and allergies. Food and Drug Administration (FDA) approved indications are for adults and adolescents (12 years of age and older) who have moderate-to-severe persistent asthma, a positive skin test, or in vitro reactivity to a perennial aeroallergen, and whose symptoms are inadequately controlled with inhaled corticosteroids. Omalizumab dosing is based on body weight and pretreatment serum total IgE level. A course of treatment is given every two to four weeks indefinitely. The maximum dosage is 375 mg every two weeks or 300 mg every four weeks based on initial IgE.

Omalizumab is administered by the subcutaneous route; however, due to the potential for adverse effects, it must be given in the physician's office or facility and is not considered a self-administered drug.

**COVERAGE**

**BlueCHiP for Medicare |**

**Commercial |**

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage or Subscriber Agreement for applicable durable medical equipment/prosthesis benefits/coverage.

**CODING**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2357</td>
<td>Injection,omalizumab, 5 mg</td>
</tr>
<tr>
<td>96372</td>
<td></td>
</tr>
</tbody>
</table>

**RELATED POLICIES**

Not applicable.

**PUBLISHED**

<table>
<thead>
<tr>
<th>Update Type</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider</td>
<td>Sep 2013</td>
</tr>
<tr>
<td>Provider</td>
<td>Jul 2012</td>
</tr>
<tr>
<td>Provider</td>
<td>Mar 2011</td>
</tr>
<tr>
<td>Provider</td>
<td>Apr 2010</td>
</tr>
<tr>
<td>Provider</td>
<td>Dec 2009</td>
</tr>
<tr>
<td>Policy</td>
<td>Jan 2008</td>
</tr>
<tr>
<td>Policy</td>
<td>Dec 2006</td>
</tr>
<tr>
<td>Policy</td>
<td>Oct 2005</td>
</tr>
</tbody>
</table>
REFERENCES


This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.